腔内放射免疫化学治疗晚期食管癌  

THE INTRACAVITY CHEMO IMMUNO RADIOTHERAPY OF ADVANCED CANCER OF THE ESOPHAGUS UNDER DIRECT VISION OF ENDOSCOPE

作　　者：陈洪来[1] 赵存新[1] 赵洪滨 张银华[1] 王志英 武春荣[1] 赵莉[1] 董涛[1] 

机构地区：[1]潍坊医学院附属青州医院

出　　处：《中华消化内镜杂志》1997年第3期160-162,共3页Chinese Journal of Digestive Endoscopy

摘　　要：为了观察腔内免疫放化治疗晚期食管癌的效果，选择经Ｘ线、胃镜及病理检查确诊的晚期食管癌３２例，随机分为两组。治疗组在内镜直视下腔内注射放射性３２Ｐ、丝裂霉素Ｃ、长春新硷及卡介苗，每月１次；对照组给予５－ＦＵ及米托蒽醌，静脉注射，每月１次，或口服ＦＴ２０７。结果有效率（ＣＲ＋ＰＲ）治疗组为８１．３％，对照组为２５％（Ｐ＜０．０１）；一年生存率治疗组为４３．８％，对照组为６．２％（Ｐ＜０．０１）；一般状况评分（按ＷＨＯ五级分类）２级以上者治疗组占９３．７％，对照组占３７．５％（Ｐ＜０．０１），说明腔内免疫放化疗可明显延长患者的生存期并提高患者的生存质量。Thirty two cases of advanced of the esophangeal cancer diagnosed and ascertained by x rays;gastroscopy and pathology were divided into two groups at random. The experimental group recieved the intracavity injection of radioactive 32 P,Mitomycin C,VCR and BCG under the directvision of endoscope once per month; The contral group underwent intravenous of 5 FU and Mitoxantrone once per month or accepted FT207 orally. The effective rate (CR+PR) of the experimental and control group was the survival rate 81 3% and 25% respectively( P <0 01). One year later after the treatment in the experimental group was 43 8% and the contral group was 6 2%( P <0 01).According to the 5 degree classification of WHO, the general evaluation reached the 2nd degree in the experimental group was 93 7% in contrast to 37 5% in contral group ( P <0 01), It is suggested that the intracavity chemo immuno radiotherapy can prolong the life expectency remarkably and improve the living quality of the patient.

关 键 词：食管肿瘤 免疫疗法 放射疗法 药物疗法 

分 类 号：R735.105[医药卫生—肿瘤]